Atossa Therapeutics ATOS

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.00 (+0.39%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Atossa Therapeutics (ATOS)
    Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $0.7376

    • Market Cap

      $92.79 Million

    • Price-Earnings Ratio

      -3.35

    • Total Outstanding Shares

      125.80 Million Shares

    • Total Employees

      10

    • Dividend

      No dividend

    • IPO Date

      November 8, 2012

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      10202 5th avenue ne, Seattle, WA, 98125

    • Homepage

      https://www.atossatherapeutics.com

    Historical Stock Splits

    If you bought 180 shares of ATOS before August 26, 2016, you'd have 1 share today.
    Execution DateSplit Amount
    April 20, 20181-for-12 (Reverse Split)
    August 26, 20161-for-15 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities$-19.55 Million
    Net Cash Flow, Continuing$-19.27 Million
    Net Cash Flow From Investing Activities$-19,000
    Net Cash Flow From Financing Activities$304,000
    Net Cash Flow$-19.27 Million
    Net Cash Flow From Financing Activities, Continuing$304,000

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Revenues$0
    Income Tax Expense/Benefit$0
    Other Operating Expenses$13.12 Million
    Basic Average Shares$251.04 Million
    Operating Income/Loss$-29.49 Million
    Net Income/Loss Attributable To Parent$-26.91 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-26.91 Million
    Comprehensive Income/Loss$-26.91 Million
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Current Liabilities$5.80 Million
    Accounts Payable$1.56 Million
    Equity Attributable To Parent$73.68 Million
    Other Current Liabilities$3.17 Million
    Equity Attributable To Noncontrolling Interest$0
    Assets$79.48 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ATOS from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      â“’ 2025 Financhle. All Rights Reserved.